Pseudomonas pseudomallei is the causative agent ofmelioidosis, which was first described in 1912 in Myanmar (11) . The organism can be found in water and wet soil, with seasonal variations in its incidence in tropical, endemic areas, especially Southeast Asia and northern Australia (1, 11, 13, 18) . Case reports in those areas have shown both an increasing incidence and a changing spectrum of infection (3, 18) . P. pseudomallei infects the human body via several routes, such as respiratory and cutaneous (18) . On the basis of the clinical manifestations, the infection is classified into three main categories: asymptomatic, localized, and septicemic (3, 18) . The last form causes the highest mortality. P. pseudomallei may cause an intracellular infection (18) . Although patients with melioidosis have been treated with antimicrobial agents, treatment is still a great problem, with a high mortality in the case of the septicemic form. Moreover, drug (chloramphenicol)-resistant isolates of P. pseudomallei have been noted since 1988 (7) .
In this study, we investigated the in vitro susceptibility of P. pseudomallei isolated in Thailand to various antimicrobial agents. The agents included those which have recently been recommended for the treatment of infections caused by P. aeruginosa.
All the P. pseudomallei strains used were clinical isolates. Of those, 27 strains were isolated in Ubon-Rajathanee, Thailand, in 1989, and the remaining 70 strains were collected in the Department of Medical Sciences, Soi Bamrasnaradura Hospital, Nonthaburi, Thailand, from 1981 to 1989. They were isolated from patients with skin or soft tissue infections (pus), with respiratory tract infections (throat swab and sputum), with septicemia (blood), with splenic abscesses (pus), or with urinary tract infections (urine).
The antimicrobial agents were kindly provided by their manufacturers. Norfloxacin, enoxacin, ofloxacin, ciprofloxacin, lomefloxacin (SC-47111; NY-198 [21] ), fleroxacin (Ro 23-6240; AM833 [5] ), temafloxacin (TA167 [10] ), and tosufloxacin (T-3262 [9] ) were categorized as a newer class of quinolones (6, 22) as opposed to an older class of agents, * Corresponding author. such as that represented by nalidixic acid. Antimicrobial agents used as broad-spectrum cephems were cefuzonam, cefotaxime, ceftazidime, cefepime (14) , and E1040 (19) . Those used as carbapenems were imipenem, CS-533 (RS-533 [17] ), and meropenem (SM-7338 [8] ). Monobactam antimicrobial agents used were aztreonam and carumonam. Piperacillin was used as one of the penicillins which have been used for the treatment of P. aeruginosa infections. Tetracyclines used were tetracycline and minocycline; the latter possesses a more extensive ability to penetrate membranes. Sulfamethoxazole and trimethoprim were used either alone or in combination at a ratio of 5:1 instead of the conventional ratio of 19:1, on the basis of pharmacokinetic data showing that the two drugs are absorbed to different degrees within the human body (18a). Chloramphenicol, rifampin, and fosfomycin were also used. The quinolones were initially dissolved in 0.1 N NaOH. Rifampin, sulfamethoxazole, trimethoprim, and chloramphenicol were initially dissolved in methanol. The other compounds were dissolved in distilled water.
Susceptibility testing of bacterial strains was done by the agar dilution method with Mueller-Hinton agar (Difco Laboratories, Detroit, Mich.) by the standard procedure (12) . The test bacteria grown overnight at 37°C in L broth (15) were diluted to approximately 106 CFU/ml. Aliquots of the bacterial suspensions (27 samples per plate) were inoculated on the surfaces of antimicrobial agent-containing agar plates with a multiloop inoculator (Microplanter, type MIT-P; Sakuma Seisakusho Co., Ltd., Tokyo, Japan). The final inoculum size was approximately 104 CFU of bacteria per spot, and incubation was done for 20 h at 37°C. The MIC was defined as the lowest concentration of an antimicrobial agent that allowed no visible growth of bacteria, fewer than five very tiny colonies, or a barely visible haze in the area of the spot on the agar plate (12) . Escherichia coli NIHJ and Staphylococcus aureus 209P were used as reference strains for quality control (12) .
The MICs of each antimicrobial agent against P. pseudomallei are summarized in Table 1 . Several antimicrobial agents in the groups of newer quinolones, broad-spectrum cephems, carbapenems, monobactams, penicillins, and (2, 4, 16, 20) . We showed here that some additional antimicrobial agents have good in vitro activity against P. pseudomallei and that the incidence of drug-resistant isolates is still extremely low with P. pseudomallei. The possibility exists that tosufloxacin, ciprofloxacin, and minocycline may also be active against intracellular infections caused by P. pseudomallei.
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